Cordeddu et al recently reported the discovery of a specific SHOC2 gene mutation underlying a variant of the neuro-cardio-facio-cutaneous (NCFC) syndrome family. 1 The common denominator of mutations associated with this group of disorders is their involvement in the dysregulation of the Ras-mitogen-activated protein kinase (MAPK) pathway. 2 Mutant SHOC2 undergoes aberrant N-myristoylation that results in constitutive membrane targeting. This in turn is thought to sustain RAF1-stimulated MAPK activation. 1 The Ras-MAPK pathway is central also to the pathophysiology of juvenile myelomonocytic leukemia (JMML) and related myeloproliferative neoplasms. 3 Leukemogenic perturbation of the Ras-MAPK pathway in nonsyndromic children results from somatic lesions of the same genes that cause NCFC syndromes when mutated in the germ line, as exemplified by PTPN11 4 and KRAS. 5 Moreover, some disorders of the NCFC spectrum (notably Noonan syndrome and neurofibromatosis type 1 [NF-1]) constitute a predisposition for the development of myeloproliferative neoplasms in childhood.
